On-Demand Events


Emerging Therapies for the Management of Castration-Sensitive Prostate Cancer
Prostate cancer is the second most common cancer, after skin cancer, among men. It is the second leading cause of cancer death in the United States. With the recent drug approvals and updates to clinical practice guidelines, several knowledge, competence, and performance gaps exist in the optimal management of metastatic castration-sensitive prostate cancer (mCSPC).

This webinar addresses some of the challenges in optimal sequencing of care in mCSPC and strategies for translating new research into patient care strategies.

Presented by:

Pedro C. Barata, MD, MSC
Assistant Professor, Deming Department of Medicine Division of Hematology/Oncology, Genitourinary Cancers
Tulane University

Lisa M. Holle, PharmD, BCOP, FHOPA
Associate Clinical Professor, UConn School of Pharmacy
Associate Professor, UConn School of Medicine


This activity was in collaboration with the Association of Community Cancer Centers (ACCC). 

ACCCeLearning-OSS - 500x135

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us